ReviewVirology journal2023
An overview on the treatments and prevention against COVID-19.
Review in Virology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Randomised, Placebo-Controlled, Double-Blind Trial to Assess Efficacy and Safety of ELOM-080 in Outpatients with COVID-19.Advances in therapy · 2025Trial
- Trial
- One-pot synthesis and biological evaluation of substituted 7-chloroindolizines as antimicrobial, antioxidant, and anti-inflammatory agents.Molecular diversity · 2026Article
- Article
- Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study.BMC primary care · 2026Article
- Incentive Spirometer in COVID-19: A Systematic Review.Journal of clinical medicine · 2026Review
- Garlic-Derived Phytochemical Candidates Predicted to Disrupt SARS-CoV-2 RBD-ACE2 Binding and Inhibit Viral Entry.Molecules (Basel, Switzerland) · 2025Article
- Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data.Journal of clinical medicine · 2025Article
- Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Therapeutic efficacy of ozonated blood in severe COVID-19 patients: a randomized controlled trial.Frontiers in medicine · 2025Article
- Article
- Macrophage‑driven pathogenesis in acute lung injury/acute respiratory disease syndrome: Harnessing natural products for therapeutic interventions (Review).Molecular medicine reports · 2025Review
- Ideological Consistency and News Sharing as Predictors of Masking Among College Students.International journal of environmental research and public health · 2024Article
- Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action.Interdisciplinary sciences, computational life sciences · 2024Article
- Oral complications during the two waves of COVID-19 pandemic in China: a prospective cross-section analysis of 510 cases using questionnaire.BMC oral health · 2024Article
- Did the COVID-19 Pandemic Affect the Stress Levels among the Mothers of Premature Infants? A Narrative Review of the Present State of Knowledge, Prevention Strategies, and Future Directions.International journal of environmental research and public health · 2024Review
- A Natural Bioactive Peptide fromInternational journal of molecular sciences · 2024Article
- The role of hematological parameters in asymptomatic and non-severe cases of Omicron variant infection.Virology journal · 2024Article
- The metabolic footprint of Vero E6 cells highlights the key metabolic routes associated with SARS-CoV-2 infection and response to drug combinations.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs.
resultThere are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials.
conclusionThis review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.